|
1
|
Economopoulos T, Asprou N, Stathakis N,
Papageorgiou E, Dervenoulas J, Xanthaki K and Raptis S: Primary
extranodal non-Hodgkin's lymphoma in adults: Clinicopathological
and survival characteristics. Leuk Lymphoma. 21:131–136. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vitolo U, Seymour JF, Martelli M,
Illerhaus G, Illidge T, Zucca E, Campo E, Ladetto M and
ESMOGuidelines Committee: Extranodal diffuse large B-cell lymphoma
(DLBCL) and primary mediastinal B-cell lymphoma: ESMO clinical
practice guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 27(Suppl 5): v91–v102. 2016.PubMed/NCBI
|
|
3
|
Rudders RA, Ross ME and DeLellis RA:
Primary extranodal lymphoma: Response to treatment and factors
influencing prognosis. Cancer. 42:406–416. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Paryani S, Hoppe RT, Burke JS, Sneed P,
Dawley D, Cox RS, Rosenberg SA and Kaplan HS: Extralymphatic
involvement in diffuse non-Hodgkin's lymphoma. J Clin Oncol.
1:682–688. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
D'amore F, Christensen BE, Brincker H,
Pedersen NT, Thorling K, Hastrup J, Pedersen M, Jensen MK, Johansen
P and Andersen E: Clinicopathological features and prognostic
factors in extranodal non-hodgkin lymphomas. Danish LYFO study
group. Eur J Cancer. 27:1201–1208. 1991. View Article : Google Scholar
|
|
6
|
AlShemmari SH, Ameen RM and Sajnani KP:
Extranodal lymphoma: A comparative study. Hematology. 13:163–169.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yun J, Kim SJ, Won JH, Choi CW, Eom HS,
Kim JS, Kim MK, Kwak JY, Kim WS and Suh C: Clinical features and
prognostic relevance of ovarian involvement in non-Hodgkin's
lymphoma: A Consortium for Improving Survival of Lymphoma (CISL)
report. Leuk Res. 34:1175–1179. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Freeman C, Berg JW and Cutler SJ:
Occurrence and prognosis of extranodal lymphomas. Cancer.
29:252–260. 1972. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Reddy S, Pellettiere E, Saxena V and
Hendrickson FR: Extranodal non-Hodgkin's lymphoma. Cancer.
46:1925–1931. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang J, Chen B and Xu X: Impact of
rituximab on incidence of and risk factors for central nervous
system relapse in patients with diffuse large B-cell lymphoma: A
systematic review and meta-analysis. Leuk Lymphoma. 55:509–514.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jaffe ES: The 2008 WHO classification of
lymphomas: Implications for clinical practice and translational
research. Hematology Am Soc Hematol Educ Program. 523–531:2009.
|
|
12
|
Carbone PP, Kaplan HS, Musshoff K,
Smithers DW and Tubiana M: Report of the committee on hodgkin's
disease staging classification. Cancer Res. 31:1860–1861.
1971.PubMed/NCBI
|
|
13
|
International Non-Hodgkin's Lymphoma
Prognostic Factors Project: A predictive model for aggressive
non-Hodgkin's lymphoma. N Engl J Med. 329:987–994. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cheson BD, Fisher RI, Barrington SF,
Cavalli F, Schwartz LH, Zucca E and Lister TA: Recommendations for
initial evaluation, staging, and response assessment of Hodgkin and
non-Hodgkin lymphoma: The Lugano classification. J Clin Oncol.
32:3059–3068. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zelenetz AD, Gordon LI, Wierda WG,
Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd
JC, Czuczman MS, et al: Non-Hodgkin's lymphomas, version 2.2014. J
Natl Compr Canc Netw. 12:916–946. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cheson BD, Pfistner B, Juweid ME, Gascoyne
RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca
E, et al: Revised response criteria for malignant lymphoma. J Clin
Oncol. 25:579–586. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the eastern cooperative oncology group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
A clinical evaluation of the international
lymphoma study group classification of non-hodgkin's lymphoma: The
non-hodgkin's lymphoma classification project. Blood. 89:3909–3918.
1997.PubMed/NCBI
|
|
19
|
Armitage JO and Weisenburger DD: New
approach to classifying non-Hodgkin's lymphomas: Clinical features
of the major histologic subtypes. Non-hodgkin's lymphoma
classification project. J Clin Oncol. 16:2780–2795. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Khosla D, Kumar R, Kapoor R, Kumar N, Bera
A and Sharma SC: A retrospective analysis of clinicopathological
characteristics, treatment, and outcome of 27 patients of primary
intestinal lymphomas. J Gastrointest Cancer. 44:417–421. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gou H, Zang J, Jiang M, Yang Y, Cao D and
Chen X: Clinical prognostic analysis of 116 patients with primary
intestinal non-hodgkin lymphoma. Med Oncol. 29:227–234. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim SJ, Choi CW, Mun Y, Oh SY, Kang HJ,
Lee SI, Won JH, Kim MK, Kwon JH, Kim JS, et al: Multicenter
retrospective analysis of 581 patients with primary intestinal
non-hodgkin lymphoma from the Consortium for Improving Survival of
Lymphoma (CISL). BMC Cancer. 11:3212011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim SJ, Kang HJ, Kim JS, Oh SY, Choi CW,
Lee SI, Won JH, Kim MK, Kwon JH, Mun Y, et al: Comparison of
treatment strategies for patients with intestinal diffuse large
B-cell lymphoma: Surgical resection followed by chemotherapy versus
chemotherapy alone. Blood. 117:1958–1965. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Frey NV, Svoboda J, Andreadis C, Tsai DE,
Schuster SJ, Elstrom R, Rubin SC and Nasta SD: Primary lymphomas of
the cervix and uterus: The University of Pennsylvania's experience
and a review of the literature. Leuk Lymphoma. 47:1894–1901. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Miller TP, Dahlberg S, Cassady JR,
Adelstein DJ, Spier CM, Grogan TM, LeBlanc M, Carlin S, Chase E and
Fisher RI: Chemotherapy alone compared with chemotherapy plus
radiotherapy for localized intermediate- and high-grade
non-Hodgkin's lymphoma. N Engl J Med. 339:21–26. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cheng H, Tang X, Cheng J, Zhang B, Zhang
YL, Wang WQ and Teng P: Pathologic character and diagnosis of
female primary genital system diffuse large B cell lymphoma. Eur
Rev Med Pharmacol Sci. 21:1471–1476. 2017.PubMed/NCBI
|
|
27
|
Aviv A, Tadmor T and Polliack A: Primary
diffuse large B-cell lymphoma of the breast: Looking at
pathogenesis, clinical issues and therapeutic options. Ann Oncol.
24:2236–2244. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jennings WC, Baker RS, Murray SS, Howard
CA, Parker DE, Peabody LF, Vice HM, Sheehan WW and Broughan TA:
Primary breast lymphoma: The role of mastectomy and the importance
of lymph node status. Ann Surg. 245:784–789. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ryan G, Martinelli G, Kuper-Hommel M,
Tsang R, Pruneri G, Yuen K, Roos D, Lennard A, Devizzi L, Crabb S,
et al: Primary diffuse large b-cell lymphoma of the breast:
Prognostic factors and outcomes of a study by the international
extranodal lymphoma study group. Ann Oncol. 19:233–241. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ha CS, Shadle KM, Medeiros LJ, Wilder RB,
Hess MA, Cabanillas F and Cox JD: Localized non-Hodgkin lymphoma
involving the thyroid gland. Cancer. 91:629–635. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pyke CM, Grant CS, Habermann TM, Kurtin
PJ, van Heerden JA, Bergstralh EJ, Kunselman A and Hay ID:
Non-Hodgkin's lymphoma of the thyroid: Is more than biopsy
necessary? World J Surg. 16:604–609; discussion 609-10. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Meyer-Rochow GY, Sywak MS, Reeve TS,
Delbridge LW and Sidhu SB: Surgical trends in the management of
thyroid lymphoma. Eur J Surg Oncol. 34:576–580. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Abrey LE, Ben-Porat L, Panageas KS,
Yahalom J, Berkey B, Curran W, Schultz C, Leibel S, Nelson D, Mehta
M and DeAngelis LM: Primary central nervous system lymphoma: The
memorial sloan-kettering cancer center prognostic model. J Clin
Oncol. 24:5711–5715. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ferreri AJ, Reni M, Foppoli M, Martelli M,
Pangalis GA, Frezzato M, Cabras MG, Fabbri A, Corazzelli G,
Ilariucci F, et al: High-dose cytarabine plus high-dose
methotrexate versus high-dose methotrexate alone in patients with
primary CNS lymphoma: A randomised phase 2 trial. Lancet.
374:1512–1520. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ferreri AJ, Cwynarski K, Pulczynski E,
Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosee PL, Schorb
E, et al: Chemoimmunotherapy with methotrexate, cytarabine,
thiotepa, and rituximab (matrix regimen) in patients with primary
cns lymphoma: Results of the first randomisation of the
international extranodal lymphoma study group-32 (ielsg32) phase 2
trial. Lancet Haematol. 3:e217–e227. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hoang-Xuan K, Bessell E, Bromberg J,
Hottinger AF, Preusser M, Ruda R, Schlegel U, Siegal T, Soussain C,
Abacioglu U, et al: Diagnosis and treatment of primary CNS lymphoma
in immunocompetent patients: Guidelines from the european
association for neuro-oncology. Lancet Oncol. 16:e322–e332. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Morris PG, Correa DD, Yahalom J, Raizer
JJ, Schiff D, Grant B, Grimm S, Lai RK, Reiner AS, Panageas K, et
al: Rituximab, methotrexate, procarbazine, and vincristine followed
by consolidation reduced-dose whole-brain radiotherapy and
cytarabine in newly diagnosed primary CNS lymphoma: Final results
and long-term outcome. J Clin Oncol. 31:3971–3979. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Pels H and Schlegel U: Primary central
nervous system lymphoma. Curr Treat Options Neurol. 8:346–357.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shah GD, Yahalom J, Correa DD, Lai RK,
Raizer JJ, Schiff D, LaRocca R, Grant B, DeAngelis LM and Abrey LE:
Combined immunochemotherapy with reduced whole-brain radiotherapy
for newly diagnosed primary CNS lymphoma. J Clin Oncol.
25:4730–4735. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Thiel E, Korfel A, Martus P, Kanz L,
Griesinger F, Rauch M, Roth A, Hertenstein B, von Toll T,
Hundsberger T, et al: High-dose methotrexate with or without whole
brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): A phase
3, randomised, non-inferiority trial. Lancet Oncol. 11:1036–1047.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Herrlinger U, Schafer N, Fimmers R,
Griesinger F, Rauch M, Kirchen H, Roth P, Glas M, Bamberg M, Martus
P, et al: Early whole brain radiotherapy in primary CNS lymphoma:
Negative impact on quality of life in the randomized G-PCNSL-SG1
trial. J Cancer Res Clin Oncol. 143:1815–1821. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
DeAngelis LM, Seiferheld W, Schold SC,
Fisher B and Schultz CJ; Radiation Therapy Oncology Group Study
93–10: Combination chemotherapy and radiotherapy for primary
central nervous system lymphoma: Radiation therapy oncology group
study 93-10. J Clin Oncol. 20:4643–4648. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Grommes C, Pastore A, Palaskas N, Tang SS,
Campos C, Schartz D, Codega P, Nichol D, Clark O, Hsieh W, et al:
Ibrutinib unmasks critical role of bruton tyrosine kinase in
primary cns lymphoma. Cancer Discov. 7:1018–1029. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Nayak L, Iwamoto FM, LaCasce A, Mukundan
S, Roemer MGM, Chapuy B, Armand P, Rodig SJ and Shipp MA: PD-1
blockade with nivolumab in relapsed/refractory primary central
nervous system and testicular lymphoma. Blood. 129:3071–3073. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Montesinos-Rongen M, Godlewska E, Brunn A,
Wiestler OD, Siebert R and Deckert M: Activating L265P mutations of
the MYD88 gene are common in primary central nervous system
lymphoma. Acta Neuropathol. 122:791–792. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kim Y, Ju H, Kim DH, Yoo HY, Kim SJ, Kim
WS and Ko YH: CD79B and MYD88 mutations in diffuse large B-cell
lymphoma. Hum Pathol. 45:556–564. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zheng M, Perry AM, Bierman P, Loberiza F
Jr, Nasr MR, Szwajcer D, Del Bigio MR, Smith LM, Zhang W and
Greiner TC: Frequency of MYD88 and CD79B mutations, and MGMT
methylation in primary central nervous system diffuse large B-cell
lymphoma. Neuropathology. 37:509–516. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Berghoff AS, Ricken G, Widhalm G, Rajky O,
Hainfellner JA, Birner P, Raderer M and Preusser M: PD1 (CD279) and
PD-L1 (CD274, B7H1) expression in primary central nervous system
lymphomas (PCNSL). Clin Neuropathol. 33:42–49. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chapuy B, Roemer MG, Stewart C, Tan Y, Abo
RP, Zhang L, Dunford AJ, Meredith DM, Thorner AR, Jordanova ES, et
al: Targetable genetic features of primary testicular and primary
central nervous system lymphomas. Blood. 127:869–881. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Pfreundschuh M, Kuhnt E, Trumper L,
Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell
R, Jaeger U, et al: CHOP-like chemotherapy with or without
rituximab in young patients with good-prognosis diffuse
large-B-cell lymphoma: 6-year results of an open-label randomised
study of the mabthera international trial (MInT) group. Lancet
Oncol. 12:1013–1022. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Li X, Shen W, Cao J, Wang J, Chen F, Wang
C, Zou S, Shen B, Zhao R, Li J and Shen Z: Treatment of
gastrointestinal diffuse large B cell lymphoma in China: A 10-year
retrospective study of 114 cases. Ann Hematol. 91:1721–1729. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kim YR, Kim JS, Min YH, Hyunyoon D, Shin
HJ, Mun YC, Park Y, Do YR, Jeong SH, Park JS, et al: Prognostic
factors in primary diffuse large B-cell lymphoma of adrenal gland
treated with rituximab-CHOP chemotherapy from the consortium for
improving survival of lymphoma (CISL). J Hematol Oncol. 5:492012.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Aviles A, Neri N and Nambo MJ: The role of
genotype in 104 cases of diffuse large B-cell lymphoma primary of
breast. Am J Clin Oncol. 35:126–129. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Hu S, Song Y, Li Y, Sun X, Su L, Zhang W,
Jia J, Bai O, Liang R, Li X, et al: Primary breast diffuse large B
cell lymphoma in the rituximab era: Outcomes of a multicenter
retrospective study by the lymphoma and leukemia committee of
chinese geriatric oncology society(LLC-CGOS). Blood.
128:42282016.
|
|
55
|
Sun Y, Joks M, Xu LM, Chen XL, Qian D, You
JQ and Yuan ZY: Diffuse large B-cell lymphoma of the breast:
Prognostic factors and treatment outcomes. Onco Ther. 9:2069–2080.
2016. View Article : Google Scholar
|
|
56
|
Nyman H, Adde M, Karjalainen-Lindsberg ML,
Taskinen M, Berglund M, Amini RM, Blomqvist C, Enblad G and Leppa
S: Prognostic impact of immunohistochemically defined germinal
center phenotype in diffuse large B-cell lymphoma patients treated
with immunochemotherapy. Blood. 109:4930–4935. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Choi WW, Weisenburger DD, Greiner TC,
Piris MA, Banham AH, Delabie J, Braziel RM, Geng H, Iqbal J, Lenz
G, et al: A new immunostain algorithm classifies diffuse large
B-cell lymphoma into molecular subtypes with high accuracy. Clin
Cancer Res. 15:5494–5502. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Horiguchi K, Hashimoto K, Hashizume M,
Masuo T, Suto M, Okajo J, Handa H, Kaneko Y, Yokoo H, Sasaki A, et
al: Primary bilateral adrenal diffuse large B-cell lymphoma
demonstrating adrenal failure. Intern Med. 49:2241–2246. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Hosein PJ, Maragulia JC, Salzberg MP,
Press OW, Habermann TM, Vose JM, Bast M, Advani RH, Tibshirani R,
Evens AM, et al: A multicentre study of primary breast diffuse
large B-cell lymphoma in the rituximab era. Br J Haematol.
165:358–363. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Taniguchi K, Takata K, Chuang SS,
Miyata-Takata T, Sato Y, Satou A, Hashimoto Y, Tamura M, Nagakita
K, Ohnishi N, et al: Frequent MYD88 L265P and CD79B mutations in
primary breast diffuse large B-cell lymphoma. Am J Surg Pathol.
40:324–334. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Cao XX, Li J, Cai H, Zhang W, Duan MH and
Zhou DB: Patients with primary breast and primary female genital
tract diffuse large B cell lymphoma have a high frequency of MYD88
and CD79B mutations. Ann Hematol. 96:1867–1871. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Lin CH, Kuo KT, Chuang SS, Kuo SH, Chang
JH, Chang KC, Hsu HC, Tien HF and Cheng AL: Comparison of the
expression and prognostic significance of differentiation markers
between diffuse large B-cell lymphoma of central nervous system
origin and peripheral nodal origin. Clin Cancer Res. 12:1152–1156.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Braaten KM, Betensky RA, de Leval L, Okada
Y, Hochberg FH, Louis DN, Harris NL and Batchelor TT: BCL-6
expression predicts improved survival in patients with primary
central nervous system lymphoma. Clin Cancer Res. 9:1063–1069.
2003.PubMed/NCBI
|
|
64
|
Fukumura K, Kawazu M, Kojima S, Ueno T,
Sai E, Soda M, Ueda H, Yasuda T, Yamaguchi H, Lee J, et al: Genomic
characterization of primary central nervous system lymphoma. Acta
Neuropathol. 131:865–875. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Derringer GA, Thompson LD, Frommelt RA,
Bijwaard KE, Heffess CS and Abbondanzo SL: Malignant lymphoma of
the thyroid gland: A clinicopathologic study of 108 cases. Am J
Surg Pathol. 24:623–639. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Shimazu Y, Notohara K and Ueda Y: Diffuse
large B-cell lymphoma with central nervous system relapse:
Prognosis and risk factors according to retrospective analysis from
a single-center experience. Int J Hematol. 89:577–583. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Yamamoto E, Ozaki N, Nakagawa M and Kimoto
M: Primary bilateral adrenal lymphoma associated with idiopathic
thrombocytopenic purpura. Leuk Lymphoma. 35:403–408. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Sonneveld P, de Ridder M, van der Lelie H,
Nieuwenhuis K, Schouten H, Mulder A, van Reijswoud I, Hop W and
Lowenberg B: Comparison of doxorubicin and mitoxantrone in the
treatment of elderly patients with advanced diffuse non-Hodgkin's
lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol.
13:2530–2539. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Bastion Y, Blay JY, Divine M, Brice P,
Bordessoule D, Sebban C, Blanc M, Tilly H, Lederlin P, Deconinck E,
et al: Elderly patients with aggressive non-Hodgkin's lymphoma:
Disease presentation, response to treatment, and survival-a Groupe
d'Etude des Lymphomes de l'Adulte study on 453 patients older than
69 years. J Clin Oncol. 15:2945–2953. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Hayase E, Kurosawa M, Yonezumi M and
Suzuki S: Early relapse in the central nervous system-after
achieving complete response in primary vaginal lymphoma. Rinsho
Ketsueki. 53:229–234. 2012.(In Japanese). PubMed/NCBI
|
|
71
|
Yildirim Y: Primary ovarian large B-cell
lymphoma in patient with juvenile rheumatoid arthritis treated with
low dose Methotrexate. Gynecol Oncol. 97:249–252. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Cohn DE, Resnick KE, Eaton LA, deHart J
and Zanagnolo V: Non-Hodgkin's lymphoma mimicking gynecological
malignancies of the vagina and cervix: A report of four cases. Int
J Gynecol Cancer. 17:274–279. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Hollender A, Kvaloy S, Nome O, Skovlund E,
Lote K and Holte H: Central nervous system involvement following
diagnosis of non-Hodgkin's lymphoma: A risk model. Ann Oncol.
13:1099–1107. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
El-Galaly TC, Cheah CY, Hutchings M,
Mikhaeel NG, Savage KJ, Sehn LH, Barrington S, Hansen JW, Poulsen
MØ, Smith D, et al: Uterine, but not ovarian, female reproductive
organ involvement at presentation by diffuse large B-cell lymphoma
is associated with poor outcomes and a high frequency of secondary
CNS involvement. Br J Haematol. 175:876–883. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Primary adrenal lymphoma with secondary
central nervous system involvement: A case report and review of the
literature. Turk J Haematol. 30:405–408. 2013.PubMed/NCBI
|
|
76
|
Kraan W, Horlings HM, van Keimpema M,
Schilder-Tol EJ, Oud ME, Scheepstra C, Kluin PM, Kersten MJ,
Spaargaren M and Pals ST: High prevalence of oncogenic MYD88 and
CD79B mutations in diffuse large B-cell lymphomas presenting at
immune-privileged sites. Blood Cancer J. 3:e1392013. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Gonzalez-Aguilar A, Idbaih A, Boisselier
B, Habbita N, Rossetto M, Laurenge A, Bruno A, Jouvet A, Polivka M,
Adam C, et al: Recurrent mutations of MYD88 and TBL1XR1 in primary
central nervous system lymphomas. Clin Cancer Res. 18:5203–5211.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Nagakita K, Takata K, Taniguchi K,
Miyata-Takata T, Sato Y, Tari A, Ohnishi N, Noujima-Harada M, Omote
S, Nakamura N, et al: Clinicopathological features of 49 primary
gastrointestinal diffuse large B-cell lymphoma cases; comparison
with location, cell-of-origin, and frequency of MYD88 L265P. Pathol
Int. 66:444–452. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Chua SL, Seymour JF, Streater J, Wolf MM,
Januszewicz EH and Prince HM: Intrathecal chemotherapy alone is
inadequate central nervous system prophylaxis in patients with
intermediate-grade non-Hodgkin's lymphoma. Leuk Lymphoma.
43:1783–1788. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Cheah CY, Herbert KE, O'Rourke K, Kennedy
GA, George A, Fedele PL, Gilbertson M, Tan SY, Ritchie DS, Opat SS,
et al: A multicentre retrospective comparison of central nervous
system prophylaxis strategies among patients with high-risk diffuse
large B-cell lymphoma. Br J Cancer. 111:1072–1079. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Vassal G, Valteau D, Bonnay M, Patte C,
Aubier F and Lemerle J: Cerebrospinal fluid and plasma methotrexate
levels following high-dose regimen given as a 3-hour intravenous
infusion in children with nonHodgkin's lymphoma. Pediatr Hemat
Oncol. 7:71–77. 1990. View Article : Google Scholar
|
|
82
|
Arkenau HT, Chong G, Cunningham D, Watkins
D, Agarwal R, Sirohi B, Trumper M, Norman A, Wotherspoon A and
Horwich A: The role of intrathecal chemotherapy prophylaxis in
patients with diffuse large B-cell lymphoma. Ann Oncol. 18:541–545.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Boehme V, Schmitz N, Zeynalova S, Loeffler
M and Pfreundschuh M: CNS events in elderly patients with
aggressive lymphoma treated with modern chemotherapy (CHOP-14) with
or without rituximab: An analysis of patients treated in the
RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma
Study Group (DSHNHL). Blood. 113:3896–38902. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Cai QQ, Hu LY, Geng QR, Chen J, Lu ZH, Rao
HL, Liu Q, Jiang WQ, Huang HQ, Lin TY and Xia ZJ: New risk factors
and new tendency for central nervous system relapse in patients
with diffuse large B-cell lymphoma: A retrospective study. Chin J
Cancer. 35:872016. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Ichikawa S, Fukuhara N, Inoue A,
Katsushima H, Ohba R, Katsuoka Y, Onishi Y, Yamamoto J, Sasaki O,
Nomura J, et al: Clinicopathological analysis of primary adrenal
diffuse large B-cell lymphoma: Effectiveness of
rituximab-containing chemotherapy including central nervous system
prophylaxis. Exp Hematol Oncol. 2:192013. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Kridel R, Telio D, Villa D, Sehn LH,
Gerrie AS, Shenkier T, Klasa R, Slack GW, Tan K, Gascoyne RD, et
al: Diffuse large B-cell lymphoma with testicular involvement:
Outcome and risk of CNS relapse in the rituximab era. Br J
Haematol. 176:210–221. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Feugier P, Virion JM, Tilly H, Haioun C,
Marit G, Macro M, Bordessoule D, Recher C, Blanc M, Molina T, et
al: Incidence and risk factors for central nervous system
occurrence in elderly patients with diffuse large-B-cell lymphoma:
Influence of rituximab. Ann Oncol. 15:129–133. 2004. View Article : Google Scholar : PubMed/NCBI
|
